PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
Titel:
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
Auteur:
Loverix, Liselore Vergote, Ignace Busschaert, Pieter Vanderstichele, Adriaan Venken, Tom Boeckx, Bram Harter, Philipp Brems, Hilde Van Nieuwenhuysen, Els Pignata, Sandro Baert, Thaïs Gonzalez-Martin, Antonio Han, Sileny Marth, Christian Neven, Patrick Colombo, Nicoletta Berteloot, Patrick Mäenpää, Johanna Olbrecht, Siel Laga, Tina Sablon, Erwin Ray-Coquard, Isabelle Pujade-Lauraine, Eric Lambrechts, Diether Van Gorp, Toon